×
0.124260355029586 0.0650887573964498 0.0473372781065089 0.0650887573964498 0.0473372781065089 0.0355029585798817 -0.0118934911242602 -0.0226035502958579
Stockreport

SELLAS Life Sciences Announces Expedited Development Path for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Following Feedback from FDA

SELLAS Life Sciences Group, Inc (SLS)  More Company Research Source: GlobeNewswire
Last sellas life sciences group, inc earnings: 11/14 04:41 pm Check Earnings Report
PDF Agreement on new open-label randomized registrational Phase 3 study in patients in second complete remission (CR2) poised to reduce sample size, time to primary endpoint and costs Fast-Track and Orphan Drug designations for GPS in AML continue to apply NEW YORK, Nov. 28, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today provided an update on its late-stage clinical development program for the Company’s proprietary galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML).  Following a clinical and regulatory strategy defining Type C dialogue with the U.S. Food and Drug Administration (FDA), the Company plans to proceed with a clinical study design and biostatistical plan to support a Phase 3 registrational study for maintenance therapy for AML patients who have achieved compl [Read more]

IMPACT SNAPSHOT EVENT TIME: SLS
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
SLS alerts
from News Quantified
Opt-in for
SLS alerts

from News Quantified
Opt-in for
SLS alerts

from News Quantified